| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Email: |
sales@invivochem.cn |
| Products Intro: |
Product Name:MEISi-2
CAS:2375595-72-3
Purity:98% HPLC Package:1mg Remarks:V2445
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:HPK1-IN-2 dihydrochloride
CAS:2375595-72-3
Package:1removed
|
|
| | MEISi-2 Basic information |
| Product Name: | MEISi-2 | | Synonyms: | 4-amino-5-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-7H-thieno[2,3-b]pyridin-6-one | | CAS: | 2375595-72-3 | | MF: | C19H21ClN6OS | | MW: | 416.93 | | EINECS: | | | Product Categories: | | | Mol File: | 2375595-72-3.mol |  |
| | MEISi-2 Chemical Properties |
| | MEISi-2 Usage And Synthesis |
| Uses | HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 μΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 μΜ | | in vivo | HPK1-IN-2 (example A1; 75-150 mg/kg; oral gavage; daily; for 21 days) treatment shows a dose-dependently tumor growth inhibition, with 75 mg/kg and 150 mg/kg QD inhibiting tumour growth by 44% and 64%, respectively[1]. | Animal Model: | Female BALB/c mice (6-8week old) injected with CT26 cancer cells[1] | | Dosage: | 75 mg/kg and 150 mg/kg | | Administration: | Oral gavage; daily; for 21 days | | Result: | Showed a dose-dependently tumor growth inhibition. |
| | References | [1] Peter Brent Sampson, et al. Hpk1 inhibitors and methods of using same. WO2016205942A1. |
| | MEISi-2 Preparation Products And Raw materials |
|